RxDoctor Payments Data

Jose Vigario, DO

Geriatric Medicine · Monroe Township, NJNPI 1487691929

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Amgen at 27.3% of the total. Reporting peaked in 2023 at $328 and has fallen 50.6% since, to $162 in 2025.

$902in general payments, 2019–2025

Across 58 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$246
  • Merck$238
  • Novartis$61
  • GSK$57
  • Exact Sciences$55
  • Harmony Biosciences LLC$50
  • plus $195 from 8 others

What the payments were for

  • Food & beverage$902100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$902 in reported general payments places this provider in the 65th percentile of 165 geriatric medicine providers in New Jersey.

See all geriatric medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$288,695
Medicare patients
603
Services billed
3,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$89,996
JanuviaSitagliptin Phosphate36$40,705
XareltoRivaroxaban16$21,447
MyrbetriqMirabegron15$13,143
SynjardyEmpagliflozin/Metformin Hcl13$7,818
Atorvastatin Calcium484$5,981
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$4,884
Levothyroxine Sodium372$4,777
SynthroidLevothyroxine Sodium66$4,378
Rosuvastatin Calcium212$3,496
Amlodipine Besylate374$3,321
Metoprolol Succinate167$2,895
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,504
Omeprazole144$2,445
Escitalopram Oxalate170$2,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$238$40,70536 claims
Boehringer IngelheimSynjardy, Stiolto Respimat$16$12,70324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 165 geriatric medicine providers in New Jersey.

Other geriatric medicine in Monroe Township

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →